The larger contract manufacturing and development organization (CDMO) have developed an appetite for acquiring capabilities in the cell and gene therapy space.
For instance, Lonza filled a strategic gap in its own portfolio through the acquisition of PharmaCell – providing it with a base in the Netherlands with cell and gene manufacturing capabilities.
Rival CDMOs have followed suit, with large sums changing hands in the deals that saw Thermo Fisher takeover gene therapy specialist Brammer Bio and Catalent acquire Paragon.
With increased competition in the space, some have raised concerns about the numbers of talent needed to serve this space and the challenges of keeping them once hired.
BioPharma-Reporter (BPR) spoke to Marc Funk (MF), CEO of Lonza, to gain a leadership perspective about the challenges of recruiting in the space and more broadly about the challenges facing cell and gene therapy manufacture.
BPR: Cell and gene therapy space is developing quickly – how are you ensuring that talent are brought in and retained?
MF: We need to be aware of staff retention, but it's not necessarily specific to the cell and gene therapy space. The focus is training the right talent, bringing them on board, and helping the industry cope with the unmet need in cell and gene therapy. In this regard, we are not different to anybody else, but what we can say is that we do not have talent erosion – people that come to our sites are happy to stay.
BPR: What are the main challenges in cell and gene therapy?
Bagikan Berita Ini
0 Response to "Automating cell and gene therapy manufacture 'has to be accelerated', says Lonza CEO - BioPharma-Reporter.com"
Post a Comment